What You Should Know...

KEY POINTS TO BE AWARE OF REGARDING DIFFERENCES BETWEEN

ZOSTER VACCINES

	SHINGRIX (GSK) [RZV]	ZOSTAVAX (Merck) [ZVL]
Storage *View vaccine package insert for reconstitution instructions*	**Refrigerator** (between **36°F** and **46°F**) S***tore both vials together in refrigerator before reconstitution***; Protect vials from light; DO NOT FREEZE. Discard if vaccine has been frozen.	**Freezer** (between **-58°F** and **+5°F) for powder containing vial. Diluent should be stored at room temperature ((**between **68°F** and **77°F) or refrigerator** (between **36°F** and **46°F) Do not freeze diluent.** Protect vials from light.
Vaccine Type	**Recombinant, adjuvanted** (non live)	**Live**
Route of Administration	**Intramuscular (IM) – 0.5ml /dose** *If administered SQ, it is not necessary to repeat vaccination.* Shingrix should be administered immediately after reconstitution or stored in the refrigerator for up to six hours.	**Subcutaneous (SQ) – 0.65ml / dose** *If administered IM, it is not necessary to repeat vaccination*. The vaccine should be administered immediately after reconstitution to minimize loss of potency. Any unused vaccine should be discarded if not used within 30 minutes.
Dose Interval	**2 dose series**, **spaced 2 to 6 months apart.** Arrange/remind patient of second dose. Minimum interval for Shingrix immunization after Zostavax is 8 weeks.	**Single dose**
Age of Patient Recommended	**≥50 yrs old, immunocompetent adults** Even people who have had shingles or previously got Zostavax can be vaccinated with Shingrix.	**≥60 yrs old immunocompetent adults** (ACIP recommendation, FDA licensure is ≥50yo)
Adjuvant	Contains adjuvant *(vial 1 with blue-green cap/red ring contains adjuvant; vial 2 with brown cap/green ring contains antigen)*	Does not contain adjuvant *Note: liquid-containing vial is diluent that can be stored at room temperature. Powder-containing vial contains antigen and must be stored in freezer.*
Contraindications	History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX.	History of anaphylactic/ anaphylactoid reaction to gelatin, neomycin, or any other component of the vaccine; Immunosuppression or Immunodeficiency; Pregnancy.
Side Effects **Grade 3:** Severe or medically significant but not immediately life- threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care If experience side effects from vaccines, should report them to the Vaccine Adverse Event Reporting System (VAERS) through the VAERS website, or by calling 1-800-822-7967	Most people got a sore arm with mild or moderate pain after getting Shingrix, and some also had redness and swelling at site of injection. Some people felt tired, had muscle pain, a headache, shivering, fever, stomach pain, or nausea. About 1 out of 6 people experienced Grade 3 side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days. Side effects were more common in younger people. Patients might have a reaction to the first or second dose of Shingrix, or both doses. Patients may choose to take over-the-counter pain medicine such as ibuprofen or acetaminophen post-vaccination if symptoms occur. Severe allergic reactions to any vaccine are very rare.	Injection site reactions were reported, no more than 0.9% of vaccine recipients reported any given injection site symptom as grade 3. In rare instances, ZVL vaccine strain has been documented to cause disseminated rash as well as herpes zoster in immunocompetent recipients, and life-threatening and fatal complications in immunocompromised recipients. Severe allergic reactions to any vaccine are very rare.
Concomitant administration	CDC general recommendations advise that recombinant and adjuvanted vaccines, such as Shingrix, can be administered concomitantly, at different anatomic sites, with other adult vaccines. Fluad has not been evaluated. CDC is examining further.	CDC recommends that Zostavax and pneumococcal vaccine, as well as any other inactivated vaccine indicated for the patient, may be administered at the same visit.

Source: CDC website (accessed Feb 5, 2018); Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines ; Refer to product package inserts for further information.